AstraZeneca Focuses on the Discovery of Monoclonal Antibodies Neutralizing SARS-CoV-2 Virus

 AstraZeneca Focuses on the Discovery of Monoclonal Antibodies Neutralizing SARS-CoV-2 Virus

AstraZeneca Focuses on the Discovery of Monoclonal Antibodies Neutralizing SARS-CoV-2 Virus

Shots:

  • AstraZeneca highlighted its efforts towards the development of Ab against the pandemic SARS-CoV-2 virus by deploying its internal expertise and via news collaboration with government and academia
  • The Chinese Academy of Sciences and Vanderbilt University Medical Center are providing AstraZeneca with genetic sequences for Ab, discovered against SARS2-CoV-2 for further in silico and in vitro assessment
  • In collaboration with USAMRIID and the University of Maryland School of Medicine, the company will do preclinical safety and efficacy assessment in BSL3 laboratories. AstraZeneca is harnessing its agreement with DARPA for the screening of Ab which is based on their ability to bind to the spike protein with a goal for clinical evaluation in the next 3-5mos.

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: AstraZeneca

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post